What is HC Wainwright’s Forecast for KALV FY2029 Earnings?

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) – Equities researchers at HC Wainwright lowered their FY2029 earnings estimates for KalVista Pharmaceuticals in a research note issued to investors on Friday, December 6th. HC Wainwright analyst A. Fein now anticipates that the specialty pharmaceutical company will earn $1.24 per share for the year, down from their previous forecast of $1.36. HC Wainwright currently has a “Buy” rating and a $20.00 target price on the stock. The consensus estimate for KalVista Pharmaceuticals’ current full-year earnings is ($2.70) per share.

KalVista Pharmaceuticals (NASDAQ:KALV) last issued its earnings results on Thursday, September 5th. The specialty pharmaceutical company reported ($0.87) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.91) by $0.04.

Several other research firms have also weighed in on KALV. Needham & Company LLC reiterated a “buy” rating and issued a $28.00 target price on shares of KalVista Pharmaceuticals in a report on Thursday. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of KalVista Pharmaceuticals in a research note on Monday, September 9th.

KalVista Pharmaceuticals Stock Up 8.3 %

KALV stock opened at $9.81 on Monday. KalVista Pharmaceuticals has a twelve month low of $7.39 and a twelve month high of $16.88. The company has a market cap of $423.94 million, a P/E ratio of -2.70 and a beta of 0.85. The business’s fifty day moving average is $10.90 and its 200-day moving average is $11.82.

Insider Activity at KalVista Pharmaceuticals

In other KalVista Pharmaceuticals news, insider Paul K. Audhya sold 8,077 shares of the business’s stock in a transaction dated Monday, November 18th. The shares were sold at an average price of $9.26, for a total transaction of $74,793.02. Following the sale, the insider now directly owns 94,199 shares of the company’s stock, valued at $872,282.74. The trade was a 7.90 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CEO Benjamin L. Palleiko sold 14,400 shares of the company’s stock in a transaction dated Monday, November 18th. The stock was sold at an average price of $9.26, for a total value of $133,344.00. Following the sale, the chief executive officer now owns 266,598 shares in the company, valued at $2,468,697.48. The trade was a 5.12 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 24,664 shares of company stock valued at $229,723. 10.50% of the stock is owned by corporate insiders.

Institutional Trading of KalVista Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in KALV. Price T Rowe Associates Inc. MD increased its stake in shares of KalVista Pharmaceuticals by 4.5% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 22,142 shares of the specialty pharmaceutical company’s stock worth $263,000 after purchasing an additional 944 shares during the last quarter. HighVista Strategies LLC grew its holdings in KalVista Pharmaceuticals by 4.5% during the third quarter. HighVista Strategies LLC now owns 33,305 shares of the specialty pharmaceutical company’s stock worth $386,000 after purchasing an additional 1,432 shares during the period. ClariVest Asset Management LLC increased its position in KalVista Pharmaceuticals by 2.8% during the second quarter. ClariVest Asset Management LLC now owns 57,096 shares of the specialty pharmaceutical company’s stock worth $673,000 after buying an additional 1,535 shares during the last quarter. Nicholas Investment Partners LP increased its position in KalVista Pharmaceuticals by 0.9% during the second quarter. Nicholas Investment Partners LP now owns 184,358 shares of the specialty pharmaceutical company’s stock worth $2,172,000 after buying an additional 1,714 shares during the last quarter. Finally, nVerses Capital LLC bought a new stake in KalVista Pharmaceuticals in the second quarter valued at approximately $25,000.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).